Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Published online October 1, 2007
Diabetes Care 31:39-40, 2008
DOI: 10.2337/dc07-0641
© 2008 by the American Diabetes Association
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dc07-0641v1
31/1/39    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Elkind-Hirsch, K.
Right arrow Articles by Bhushan, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Elkind-Hirsch, K.
Right arrow Articles by Bhushan, R.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Clinical Care/Education/Nutrition/Psychosocial Research
Original Research

Clinical Experience With the Addition of Pramlintide in Patients With Insulin-Requiring Type 2 Diabetes

Karen Elkind-Hirsch, PHD, William J. Butler, BS, Madhu Bhushan, LCSW, David Hirsch, BS and Rajat Bhushan, MD

Metabolic Center of Louisiana Research Foundation, Baton Rouge, Louisiana

Address correspondence and reprint requests to Karen Elkind-Hirsch, PhD, Metabolic Center of Louisiana Research Foundation, 7566 Picardy Ave., Baton Rouge, LA 70808. E-mail: karen.elkind-hirsch@womans.org

The first 20% of the full text of this article appears below.


   INTRODUCTION
 
Pramlintide, a synthetic amylin analog, was approved for type 2 diabetes as an adjunct treatment in patients who have failed to achieve desired glycemic control, despite optimal insulin therapy, with or without concomitant administration of oral antidiabetes agents (1). In clinical trials, pramlintide added to insulin treatment in patients with type 2 diabetes was shown to reduce postprandial glucose levels, improve glycemic control, and promote weight loss (2–8). We reviewed the medical records of our patients with type 2 diabetes who were on pramlintide in addition to insulin treatment to assess the efficacy of mealtime pramlintide on glycemic control and cardiometabolic risk factors in a single endocrine clinical practice setting.


   RESEARCH DESIGN AND METHODS—
 
We retrospectively studied laboratory and medical parameters of 92 insulin-treated adult patients with type 2 diabetes (54 female, 38 male, aged 24–80 years) recorded at baseline, 12 ± 4 weeks, and 24 ± 4 weeks after initiating pramlintide therapy. Medical and laboratory information were pulled from the main database of the Metabolic Center of Louisiana through a query that extracted information on all patients with type 2 diabetes treated with insulin who were unable to achieve glycemic control and who had completed at least 24 weeks of pramlintide treatment from June 2005 to . . . [Full Text of this Article]

Statistical analysis

   RESULTS—
 

   CONCLUSIONS—
 

Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2008 by the American Diabetes Association.